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Background: Symptoms suggestive of functional dyspepsia (FD) and irritable bowel syndrome (IBS) frequently
overlap with those of gastroesophageal reflux disease. Despite the high prevalence of symptomatic overlap, the
underlying etiology remains poorly defined. We assessed the correlation of symptomatic relief and health-related
quality of life (HRQoL) with healing of reflux esophagitis to further derive insights into the underlying etiology.
Methods: 626 patients with reflux esophagitis were enrolled into one of two treatment groups (classical healing
concept or the complete remission concept) to investigate differences in treatment intensity. Patients were treated
with pantoprazole until esophageal mucosal healing. Remission was followed for up to 6 months without
treatment. Gastro-intestinal symptoms and HRQoL were analyzed using disease-specific, psychometrically validated
patient-reported outcome instruments (ReQuest™, GERDyzer™).
Results: Symptomatic burden reflected by ReQuest™ substantially decreased from baseline to end of treatment by
83% and 88% in either treatment group, respectively. ReQuest™ scores significantly decreased in patients with or
without heartburn and in those with symptoms suggestive of FD and IBS, indicating response of all symptom
categories to treatment (p < 0.005). Therapy-associated relief of symptoms was paralleled by substantial gains in
HRQoL, which continued to stabilize post-treatment.
Conclusions: Pantoprazole is effective in relieving upper and lower gastro-intestinal symptoms overlapping with
erosive esophagitis, and provides sustained improvement in HRQoL post-treatment. Our results propose a link
between both healing of erosive esophagitis and the slower remission of upper and lower gastro-intestinal
symptoms. Since the improvement observed is likely to be multifactorial, the possibility for an immune-mediated
etiology and identification of putative susceptibility factors by genome-wide association study may provide focus
for future research.
Trial registration: ClinicalTrials.gov identifier: NCT00325676.
Keywords: Gastroesophageal reflux disease (GERD), Functional dyspepsia (FD), Irritable bowel syndrome (IBS),
Inflammatory bowel diseases (IBD), Proton pump inhibitor (PPI)* Correspondence: moennikes@web.de
1Department of Medicine and Institute of Neurogastroenterology, Academic
Teaching Hospital Martin Luther, Charité - Universitätsmedizin Berlin,
Caspar-Theyß-Str. 27-31, 14193, Berlin, Germany
Full list of author information is available at the end of the article
© 2013 Mönnikes et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Mönnikes et al. BMC Gastroenterology 2013, 13:145 Page 2 of 10
http://www.biomedcentral.com/1471-230X/13/145Background
Gastroesophageal reflux disease (GERD) is highly prevalent
in the general population. In most cases, GERD is consid-
ered a chronic disorder requiring long-term acid suppres-
sion to maintain symptomatic remission and/or healing of
erosive esophagitis [1,2]. GERD significantly impacts on
health-related quality of life (HRQoL) [3,4]. Veldhyzen van
Zanten et al. (2012) reported a close association between
increased patient satisfaction, relief of GERD symptoms,
and improved HRQoL, with relevant associations similar to
those in other chronic diseases [5]. Additional investiga-
tions have been conducted for functional bowel disorders
such as irritable bowel syndrome (IBS), concluding that
therapeutic response is associated with improvements in
HRQoL [6]. These reports focus on qualitative or statistical
correlations, but do not propose any mechanistic psycho-
logical concept for the observed concordance.
Symptomatic overlap of GERD with gastro-intestinal
(GI) co-morbidity suggestive of functional dyspepsia
(FD) or irritable bowel syndrome (IBS) [7-10] is thought,
amongst other explanations, to contribute to partial or
complete non-response to a standard dose of proton
pump inhibitor (PPI) in a significant subset of patients
[3,5,11]. However, overlap does not appear to be static
over time as symptom categories tend to fluctuate
during long-term follow-up [8,12]. Causative patho-
mechanisms currently considered include inflamma-
tory etiologies [13,14], altered intestinal motility [15],
and visceral hypersensitivity [16], each suggesting the
need for individualized therapeutic approaches in spe-
cific patient groups.
Cumulative clinical and scientific discoveries, along with
regulatory requirements of demonstrating statistical signifi-
cance for efficacy claims, have resulted in increasingly nar-
rowly defined indications and stratified patient populations
in clinical trials. Since such an approach might not reflect
the actual patient population seeking medical help, it might
be useful to study the pharmacological management of a
real-life scenario [17], which would allow for the investiga-
tion of an overlap between GERD and symptoms suggestive
of FD and IBS. Although such a study might carry the
elevated risk of observing only a partial response to
PPI treatment in these less stringently selected patients
[5], such a design could reveal additional insights into
the inter-relationship between perceived symptoms and
HRQoL, and the pathophysiological relatedness of, or
separation between, GERD, FD, IBS and possibly early-
stage inflammatory bowel diseases (IBD).
In the current study, we therefore investigated a pa-
tient population that closely resembles the general
population affected by endosopically-confirmed GERD,
which overlaps with upper and lower GI symptom-
atology. In addition, we evaluated two treatment
groups, which modelled differences in treatmentintensity and compliance. We further hypothesized
that treatment intensity would influence patterns of
relapsing erosive esophagitis, and that the analysis of
the temporal development of overlap during treat-
ment and remission could shed additional insights
into an underlying etiology.Methods
Study design and patients
The design and primary results of this prospective
clinical trial (ClinicalTrials.gov identifier: NCT00325676)
have been previously described elsewhere [18]. This re-
port includes prospectively defined subgroup analyses
of therapy-associated changes of GI symptomatology
and HRQoL. In brief, this randomized, multicenter,
multinational, parallel group study (June 2006 to May
2007) was conducted in patients with GERD diagnosed
endoscopically according to the Los Angeles classifica-
tion (LA grade A–D) (full inclusion and exclusion cri-
teria have been previously presented [18]). To assess
the treatment effects based on duration and inten-
sity of PPI administration, patients were randomized
to two different treatment concepts: classical healing
(CH) and complete remission (CR) (Figure 1). The CH
group was treated up to 8 weeks until esophageal healing
only (according to the LA classification), whereas the
CR group was treated up to 16 weeks until ‘complete
remission’ occurred. This was defined as esophageal healing
and a ReQuest™ (Reflux Questionnaire, Nycomed GmbH,
Nycomed: a Takeda Company, Konstanz, Germany) -GI
score below the predefined symptom threshold [19].
The trial was further divided into two periods: a treat-
ment phase and a subsequent observational phase.
During the treatment phase, patients were adminis-
tered pantoprazole 40 mg od until resolution of GERD
as pre-specified for each group. Healed patients entered
an observational phase, which consisted of clinical
follow-up for up to 6 months without PPI treatment
and monitoring for endoscopically-confirmed relapse of
reflux esophagitis according to the LA classification. To
further assess concurrent symptoms affecting the upper
and lower GI tract, a questionnaire was implemented
asking for heartburn and modified symptomatic Rome
II/III criteria, the latter suggesting diagnoses of FD
and IBS [18].
The trial was performed in accordance with the Dec-
laration of Helsinki and the International Conference
on Harmonisation-Good Clinical Practice (ICH-GCP),
and was approved by the independent ethics committees
(Commission of Bioethics of Silesian Medical Chamber in
Katowice [Poland]; Pharma Ethics, and University of the
Free State Ethics Committee [South Africa]; Ärztekammer
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Figure 1 Treatment algorithm. START, V0; STOP, last visit of Observational Phase; m, months; w, weeks.
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provided written informed consent.
Assessments of GI symptoms (ReQuest™)
The course of GI symptom profiles was measured over
time using ReQuest™. ReQuest™ is a disease-specific,
self-administered and psychometrically validated patient-
reported outcome instrument designed to assess the course
of GERD symptoms [19]. It is divided into two subscales,
ReQuest™-GI (including dimensions ‘acid complaints’, ‘upper
abdominal/stomach complaints’, ‘lower abdominal/digestive
complaints’ and ‘nausea’) and ReQuest™-WSO (assessing
dimensions ‘general well-being’, ‘sleep disturbances’ and
‘other complaints’). Dimensions were assessed for frequency
and intensity, except for ‘general well-being’ where only
intensity was recorded.
Assessments of HRQoL (GERDyzer™)
Treatment-induced changes in HRQoL were assessed
using GERDyzer™ (GERD Analyzer Scale, Nycomed GmbH,Nycomed: a Takeda Company, Konstanz, Germany).
GERDyzer™ is a disease-specific, self-administered and
psychometrically validated patient-reported outcome
instrument that was developed to investigate the im-
pact of GERD on HRQoL [4]. GERDyzer™ comprises
10 dimensions of quality of life: ‘general well-being’,
‘pain/discomfort’, ‘physical health’, ‘energy’, ‘daily activ-
ities’, ‘leisure activities’, ‘social life’, ‘diet/eating/drinking
habits’, ‘mood and sleep’, and satisfaction aspects.
Statistical analysis
In general, descriptive summary statistics were deter-
mined showing parameters for location and dispersion
for continuous parameters, and frequencies and percent-
ages for categories. The course over time for mean
values of parameters is displayed graphically by line plots
comparing the respective groups of patients.
ReQuest™ total scores were analyzed using descriptive
statistics. Between-group comparisons for patients with
or without heartburn, with or without FD, and with or
Mönnikes et al. BMC Gastroenterology 2013, 13:145 Page 4 of 10
http://www.biomedcentral.com/1471-230X/13/145without IBS were performed using the Wilcoxon rank-
sum test.
HRQoL measured by GERDyzer™ was evaluated using
explorative methods. The main analysis investigated
GERDyzer™ mean sum scores. Sum scores pertaining to
the observational phase were compared between both
treatment groups using the Wilcoxon rank-sum test.
Results
Patient characteristics
Of the 634 patients who initially received study medica-
tion, 316 (49.8%) were treated according to the CH con-
cept and 318 (50.2%) according to the CR concept. Out
of the safety set of 634 patients, 539 individuals (85.0%)
were diagnosed with erosive esophagitis LA grade A–B
and 95 individuals (15.0%) with erosive esophagitis LA
grade C–D. The intention-to-treat (ITT) population
comprised 626 patients, with 313 patients being allo-
cated to each of the two treatment concepts (CH or
CR). Of these, 87 patients were enrolled in Poland (CH
45, CR 42), 301 in South Africa (CH 160, CR 141), and
238 in Germany (CH 108, CR 130). Most patients were
of white ethnicity (CH 78.6%, CR 80.8%). FD-like com-
plaints were diagnosed at baseline in 65.2% and 64.2%,
and IBS-like co-morbidity existed in 14.1% and 13.1% of
the CH and CR groups, respectively (Table 1). The num-
ber of patients in subgroups of FD and subgroups of IBS
tended to be rather small (data on file). Approximately
one-quarter of patients in each treatment group were
current smokers. Neither ReQuest™ total scores norTable 1 Demographic data and clinical disposition at
baseline (ITT, N = 626)
Variable CH group CR group
(N = 313) (N = 313)
Gender, n (%) Male 167 (53.4) 170 (54.3)
Female 146 (46.6) 143 (45.7)
Age [years], mean (SD) 50.8 (14.6) 48.8 (14.0)
Weight [kg], mean (SD) 81.8 (16.4) 83.4 (17.4)
BMI [kg/m2], mean (SD) 28.0 (5.1) 28.6 (5.7)
Race, n (%) Asian 14 (4.5) 7 (2.2)
Black 13 (4.2) 17 (5.4)
White 246 (78.6) 253 (80.8)
Other 40 (12.8) 36 (11.5)
GI comorbidities, n (%) Dyspepsia-like 204 (65.2) 201 (64.2)
IBS-like 44 (14.1) 41 (13.1)
Current smoker, n (%) 79 (25.2) 83 (26.5)
ReQuestTM total score 10.23 11.37
GERDyzerTM sum score 46.12 49.45
CH classical healing, CR complete remission, IBS irritable bowel syndrome, ITT
intention-to-treat, N number of patients, BMI body mass index, SD
standard deviation.GERDyzer™ sum scores were notably different at base-
line in the treatment arms.
Therapy-associated change in GI symptoms
The change of the GI symptom burden over time as
evaluated by ReQuest™ is shown in Figure 2. For both
treatment groups, the ReQuest™ total scores were signifi-
cantly lower at the end of pantoprazole treatment (CH
2.14, CR 1.76) than at baseline (CH 10.23, CR 11.37).
This resembles a clinically significant decrease of the
total score by 79% in the CH group and by 85% in the
CR group. This finding was paralleled by a similar time
course for the two subscales ReQuest™-GI and Re-
Quest™-WSO. The ReQuest™-GI score substantially de-
creased from baseline (CH 6.74, CR 7.29) to the end of
treatment (CH 1.12, CR 0.84), reflective of a decrease of
the GI score by 83% in the CH group and by 88% in the
CR group (Figure 2).
To evaluate the influence of concurrent symptoms af-
fecting the upper and lower GI tract, a joint analysis of
both treatment groups was performed. At baseline,
higher ReQuest™ total scores were identified in patients
with concurrent symptoms suggestive of FD (12.45) or
IBS (14.47) than in patients with (11.37) or without
(5.53) heartburn. At the end of pantoprazole treatment,
ReQuest™ scores notably decreased in patients with
(4.65) or without heartburn (1.41), and in those with
symptoms suggestive of FD (4.36) or IBS (4.04), indicat-
ing response of all symptom categories to PPI treatment.
Interestingly, the trend for higher total scores at baseline
from concomitant heartburn (11.37) to IBS (14.47) was
inverted post-treatment (heartburn 4.65, IBS 4.04). Com-
parison of ReQuest™ total scores among groups of pa-
tients with or without heartburn, FD, or IBS was
statistically significant (all, p < 0.005).
In order to further evaluate the appropriateness of
both healing concepts, courses over time of the Re-
Quest™ total score and its subscales were plotted for
both the CH and CR groups in conjunction with total
scores of a subgroup deduced from CH patients who
were endoscopically healed but not in complete remis-
sion. As can be seen from Figure 2, ReQuest™ scores
were almost 2-fold higher for patients endoscopically
healed but not in complete remission than for patients
in either the CH or CR groups, suggesting the clinical
relevance of treatment aimed at full symptomatic remis-
sion in addition to esophageal mucosal healing.
Therapy-associated change in HRQoL
Data from the HRQoL questionnaire GERDyzer™ were
available from 606 patients at baseline, with data from
3.3% of patients missing (ITT). Overall, the significant
decrease in GERDyzer™ mean sum scores during
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Figure 2 Change in gastrointestinal (GI) symptom burden. ReQuestTM total score & GI score; d, days.
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end of the treatment phase, GERDyzer™ mean sum
scores decreased by about two-thirds in each of the two
treatment schedules investigated, with most of the effect
achieved during the first 4 weeks of pantoprazole treat-
ment (i.e., at the first study visit post-baseline). Substan-
tial gains in HRQoL resulted from a major decrease in




































Figure 3 Change in health-related quality of life. HRQoL, GERDyzerTM s
the study; d, days (A), classical healing group; (B), complete remission grouThere was no significant difference in GERDyzer™ sum
scores between the two groups studied. HRQoL mea-
sured by GERDyzer™ further improved for the CH and
CR group during the observational phase (Figure 3), as
reflected by decreasing mean sum scores. Although pa-
tients treated according to the CR concept consistently
had lower GERDyzer™ sum scores, suggesting continu-
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nificant difference in HRQoL between the two treatment
concepts studied.
In order to further assess both healing concepts re-
garding improvements in HRQoL, GERDyzer™ scores for
the CH and CR groups were analyzed in relation to
scores of a subgroup deduced from CH patients who
were endoscopically healed but not in complete remis-
sion (i.e., not achieving symptomatic relief to a level of
healthy individuals). As with the ReQuest™ scores for
these three groups, GERDyzer™ scores in the CH and
CR groups were approximately only half the scores of
patients endoscopically healed but not in complete re-
mission, thus indicating notably impaired HRQoL in pa-
tients achieving esophageal healing only (data on file).
Adverse events
Because patients randomized to CR remained in the ac-
tive treatment phase notably longer than patients allo-
cated to CH, a direct comparison of the incidence of
adverse events has to be conducted carefully. Duration
of exposure in the CH group was 42.3 ± 14.8 days com-
pared with 56.8 ± 31.5 days in the CR group (ITT),
which resembles an increase in exposure from CH to CR
of 34%. Of the 634 patients in the safety set, 175 (27.6%)
reported at least one treatment-emergent adverse event
(TEAE), most of which were mild-to-moderate in inten-
sity. A total of 81 of 316 patients (25.6%) in the CH
group and 94 of 318 patients (29.6%) in the CR group
experienced at least one TEAE, reflective of a difference
in TEAE of 4% between the two groups studied. In rela-
tion to the increase in exposure of 34%, a parallel in-
crease in TEAEs of 4% suggests that most TEAEs were
not causally related to the intake of pantoprazole. This
was further substantiated by the investigators’ causality
assessment, in which 84% of TEAEs in the CH group
and 79% of TEAEs in the CR group were considered as
‘not related’ or ‘unlikely related’ to the intake of the
study medication.
Discussion
Clinical trials often include narrowly defined clinical in-
dications and thus patient populations in order to meet
regulatory or scientific requirements. In contrast, in the
present study we used a scenario that was closer to real-
life to investigate clinical and psychometric responses to
PPI treatment in patients with endosopically-confirmed
GERD [17]. This was achieved by: (1) evaluating two dif-
ferent treatment concepts that modelled differences in
treatment intensity and compliance; and (2) applying
broad inclusion criteria, which allowed assessment of
overlapping GI conditions that frequently occur in se-
lected patients and in the general population [8-10,20].
Differential assessment of patient-reported outcomes byReQuest™ indicated that endoscopically healed patients
who did not achieve symptomatic remission to the level
of healthy individuals continued to suffer from a sub-
stantial GI symptom burden. These individuals had
symptom scores that were 2-fold higher than those in
patients with endoscopic healing and symptomatic re-
mission. This was associated with notably reduced qual-
ity of life, as indicated by scores of GERDyzer™ that were
approximately 2-fold higher than those in patients with
both endoscopic healing and symptomatic remission.
However, this differential treatment response was not
evident in the direct comparison of the original treat-
ment groups (CR and CH), for which there was no sig-
nificant difference [18]. This might be a reflection of the
number of patients who at each 4-week assessment
point were already in symptomatic remission and were
screened for endoscopic healing only. Nevertheless, the
potential clinical significance of the CR concept was re-
vealed by the cautiously implemented, pre-specified, sec-
ondary assessment of a differential subgroup of CH
patients with endoscopic healing who did not fulfil the
CR criteria.
Taken together, the analyses suggest: (1) a close correl-
ation between HRQoL and perceived GI symptoms in
GERD patients, which is consistent with previously pub-
lished research [6,20]; and (2) the clinical relevance of a
sufficient treatment effort aimed at symptomatic remis-
sion in addition to healing of the esophageal mucosa, i.e.,
until complete remission is achieved. The latter finding is
further substantiated by a recently reported long-term
clinical trial investigating pantoprazole in tertiary care
patients over the course of 15 years [2]. Analysis indicated
that the mean duration until relapse can be prolonged to
approximately 7 years by the continuous administration of
acid-suppressing medication.
To the best of our knowledge, we report for the first
time that PPI therapy can provide improvements in
HRQoL which continued to be maintained post-
treatment. This occurred despite the chronic nature of
erosive esophagitis in most patients [1]. However, this
observation might be a consequence of the close correl-
ation between perceived symptoms and HRQoL, and the
clinically meaningful difference developing towards the
end of the observational phase between the rates for re-
lapsing erosive esophagitis (65%) and GERD symptoms
(36%), indicative of a symptomatically silent disease in
many patients despite visible damage of esophageal mu-
cosa [18,21]. Thus, the delayed increase in GERD symp-
toms following relapse of erosive esophagitis appears to
be mirrored by a trend for continuously improved
HRQoL during the observational phase, until a point in
time after endoscopic relapse is met when GERD
symptom-related afferent input into the central nervous
system exceeds the threshold for entering awareness.
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tion of chronically persisting or remitting symptoms,
and thus provide the emotional basis for reduced
HRQoL.
The high number of patients in our study with base-
line dyspeptic (65%) and/or IBS-like complaints (14%)
that resemble the types of symptoms generally attributed
to functional GI disorders (FGID), such as FD and IBS,
is of note. Inter-current dyspeptic and IBS-like com-
plaints, overlapping with reflux esophagitis and GERD
symptoms has been previously described in selected
populations and in the general population [8-10,20]. Our
data, along with those of others [20], indicate signifi-
cantly increasing ReQuest™ scores (reflecting increasing
symptomatic burden) of GERD overlapping with dyspep-
tic and/or IBS-like complaints. After treatment with
pantoprazole, rates of patients fulfilling symptomatic
Rome criteria [18] and ReQuest™ scores were generally
substantially lower, indicating response of all symptom
categories to PPI treatment.
Given the overlap of GERD with dyspeptic and/or IBS-
like complaints, the question of whether or not individual
FGID are separate conditions from GERD has been raised,
and consequently different hypotheses for a possible under-
lying etiology have been proposed [13-16,18]. Etiological
hypotheses for FGID include low-level or transient in-
flammation of part of the GI tract [13,14], altered in-
testinal motility [15] or visceral hypersensitivity [16],
each of which suggests the need for different thera-
peutic approaches in specific patient groups. Ford et al.
(2010) describe a thoroughly investigated case of a
more than 2-fold increase in the prevalence of dyspep-
sia in patients suffering from transient gastroenteritis
8 years prior to conducting their investigation [13]. One
conclusion provided by the authors is that inflammation
in one part of the GI tract could induce changes of the
enteric nervous system of a non-inflamed part, a finding
previously observed in animal models. Similar reports
in humans are available on a putative pathogenic role of
low-grade inflammation, identifying increased counts of
mast cells in both the colon and upper GI tract of
subjects with IBS, potentially leading to an abnormal
interaction between mast cells and nerve fibers [14].
Such findings showing interactions between distant
parts of the GI tract via the enteric nervous system or
cells of the immune system may provide an explan-
ation as to why FD and IBS were described by others
as longitudinally unstable, fluctuating disease entities
[8,12]. This cellular cross-talk might at least partially
explain why improvements in reflux esophagitis have
beneficial effects on overlapping symptoms suggestive
of FD and IBS [18].
Evidence from distant disciplines such as molecular
biology, immunology and clinical research converges onabnormal interactions between the host and the external
human microbiome in the pathogenesis of IBS [14] and
IBD [22], establishing an etiological interface between
IBS and IBD [23]. Molecular interaction between host
cells and commensal enteric bacteria, or transient acute
gastroenteritis induced by specific pathogens, could lead
to a continuous activation of cells of the innate and ac-
quired immune system causing chronically perceived
symptoms or lasting injury to part of the GI tract. The
efficacy of antibiotic therapy in IBS and IBD provides
some support for such a patho-mechanism [22,23], al-
though theoretical interest in small intestinal bacterial
overgrowth is decreasing [23]. However, our observation
that FD and IBS symptomatology improve significantly
during PPI treatment, although at a slower rate than the
signs and symptoms of GERD [18], could possibly favour
an underlying mechanism that is primarily immune-
mediated rather than based on neural process. Such an
immune-mediated patho-mechanism would depend on
sufficient time for the clonal selection, migration, hom-
ing and peripheral dispersion of immune cells. Further
support for an immune-mediated patho-mechanism is
provided by studies that have investigated cellular and
cytokine profiles in GERD, along with the effect of PPI
treatment on them [24,25]. In such studies, PPI therapy
suppressed the expression of pro-inflammatory cyto-
kines and chemokines, such as interleukin-8 (IL-8).
Complementary studies demonstrated a reduction of
the cellular-mediated inflammatory infiltrate in the
esophageal epithelium, as represented by significantly
decreased numbers of T lymphocytes and CD8+ T
lymphocytes during PPI therapy. Interestingly, both
the levels of IL-8 and the number of T lymphocytes
have been shown to correlate with endoscopic severity
of reflux esophagitis [24,25].
Another etiological hypothesis meriting discussion is
the theoretical potential for psychiatric co-morbidity,
serving as a default diagnosis in patients complaining
about idiopathic, unpleasant perceptions or pain located
in the GI tract [26]. Such psychological disorders are de-
scribed as often preceding the onset of IBS, suggesting
they should not be considered as a consequence of suf-
fering primarily from IBS [26,27]. However, GI com-
plaints subsequent to confirmed psychiatric morbidity
could be adverse drug reactions resulting from the use
of psychotropic medication; they would thus be nosolog-
ically different to suffering from a functional GI dis-
order. Known effects of psychotropic medication occur
at a compound-specific level and are variable across in-
dividual patients [28]: (1) modulation of sensory process-
ing, involving e.g., taste [29,30], vision [31,32] and pain
[33]; (2) manipulation of the endogenous emotional
homeostasis [28,34-36]; and (3) the generation of further
adverse reactions reported to significantly affect the GI
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diarrhea [39,40,42]. Unfortunately, it is not always obvi-
ous from published reports whether or not studies have
been subject to potential confounding by the concomi-
tant use of psychotropic medication [27], or if anxiety
and depression might provide part of the natural
spectrum of an idiopathic, chronic disease being accom-
panied by pain or marked discomfort [20].
FGID and GERD are reported to cluster in families
[14,44-46]. Consequently, if an etiological genetic contri-
bution could be proven by identifying polymorphisms of
causative genes, baseline demographic data of contem-
porary clinical trials, such as that provided in Table 1,
are currently missing the evaluation of the genetic com-
position of enrolled patients. However, the challenges of
both determining a relevant set of genes and those of a
meaningful, medically actionable, integrative analysis are
well known [44,45,47,48]. In addition, different interpre-
tations of competing or additive contributions of both a
genetically imprinted trait matrix [48] and environmen-
tal health modifiers are amply discussed in the literature.
Nevertheless, the identification of key genes could be
attempted by conducting a sufficiently powered genome-
wide association study on FGID, investigating reasonably
selected patients and conditions [48]. Omitting the
known conceptual limitations of candidate gene ap-
proaches, the virtue of such an investigation would be
the identification of disease predisposing loci not being
limited to, or excluded by, specific a priori etiological
hypotheses.
Our study provides both several strengths and certain
limitations. Our study enrolled a large patient sample,
avoiding narrowly defined inclusion and exclusion cri-
teria, thus being close to a real world medical setting.
This offered the opportunity of studying interrelations
between both endoscopically-confirmed GERD and symp-
toms suggestive of FGID, and more psychometrically de-
finable conditions like HRQoL. However, due to the focus
on endoscopically-confirmed GERD (LA grades A–D),
patients with endoscopy-negative GERD or those with
purely functional symptoms were not included in our
investigation. Despite the elaborate patient sample
studied, specific subtypes of FD and IBS still tended to
be relatively rare.
Conclusions
Therapy-associated changes of GI symptomatology
broadly correlated with HRQoL in patients with an
overlap of endoscopically-confirmed GERD and symp-
toms resembling FD and IBS. Furthermore, HRQoL
appears to be negatively correlated with endoscopic re-
lapses of erosive esophagitis, with the latter generally
presenting initially as a silent condition. From an etio-
logical perspective, interactions between distant partsof the GI tract via the enteric nervous system or cells
of the immune system may provide an explanation for
independent reports of FD and IBS presenting as longi-
tudinally unstable, fluctuating conditions. Since the
improvement observed is likely to be multifactorial,
this mechanistic concept may partly explain the paral-
lel improvements in reflux esophagitis and overlapping
symptoms suggestive of FD and IBS. The previously
reported observation of slower improvements in symp-
toms suggestive of FD and IBS could hint to a primarily
immune-mediated, rather than neural, etiology, which po-
tentially relies on the known time-requiring steps involved
in clonal selection, migration, homing and peripheral
dispersion of immune cells. Nevertheless, hypothesis-
free exploration of underlying patho-mechanism(s) and
investigating a potential molecular interface towards
IBD should justify conducting a sufficiently powered
and well-designed genome-wide association study. This
could be conducted both in patients suffering from func-
tional GI disorder and in those suffering from GERD with
and without symptomatic overlap.
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